Okajima Fumikazu, Sato Koichi, Kimura Takao
Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.
Endocr J. 2009;56(3):317-34. doi: 10.1507/endocrj.k08e-228. Epub 2008 Aug 28.
Plasma high-density lipoprotein (HDL) is a potent anti-atherogenic factor, a critical role of which is thought to be reverse cholesterol transport through the lipoprotein-associated apolipoprotein A-I (apoA-I). HDL also carries a potent bioactive lipid mediator, sphingosine 1-phophate (S1P), which exerts diverse physiological and pathophysiological actions in a variety of biological systems, including the cardiovascular system. In addition, HDL-associated apoA-I is known to stimulate intracellular signaling pathways unrelated to transporter activity. Mounting evidence indicates that multiple antiatherogenic or anti-inflammatory actions of HDL independent of cholesterol metabolism are mediated by the lipoprotein-associated S1P through S1P receptors and by apoA-I through scavenger receptor class B type I.
血浆高密度脂蛋白(HDL)是一种强大的抗动脉粥样硬化因子,其关键作用被认为是通过脂蛋白相关载脂蛋白A-I(apoA-I)进行逆向胆固醇转运。HDL还携带一种强大的生物活性脂质介质,鞘氨醇-1-磷酸(S1P),它在包括心血管系统在内的多种生物系统中发挥多种生理和病理生理作用。此外,已知HDL相关的apoA-I可刺激与转运体活性无关的细胞内信号通路。越来越多的证据表明,HDL独立于胆固醇代谢的多种抗动脉粥样硬化或抗炎作用是由脂蛋白相关的S1P通过S1P受体以及由apoA-I通过B类I型清道夫受体介导的。